Abstract:We propose a non-invasive, folate receptor (FR)–based circulating tumor cell (CTC) detection approach to interpret treatment response of targeted therapy between baseline and follow-up CTC values and the feasibility whether CTCs as a prognostic factor in advanced NSCLC with EGFR mutation/ALK translocation. This was a prospective, unopen-labeled, single-center trial. From July 25, 2014 to March 11,2016, 308 advanced NSCLC patients were enrolled to quantified CTC level by negative enrichment using immunomagnetic beads in combination with folate receptor-directed polymerase chain reaction(PCR) that allows secondary amplification of tiny amounts of CTCs in 3mL peripheral blood before the start of targeted therapy and after one month, every two months hereafter of treatment. Among whom, 272 NSCLC patients with EGFR mutation (exon 19Del mutation: n=135, L858R mutation: n=137), 39 ALK translocation or undefined lung cancer patients. Sequential analyses were conducted to monitor CTC values during therapy and correlate radiological effects with treatment outcome. There was no significant difference between CTC values and patients’ characteristics including stage (P= 0.1015), EGFR mutation status (19 del:14.5 CTCs, L858R:12.6 CTCs, P=0.1868), age (≤60 versus >60 years), gender, smoking status. Of 272 eligible and evaluable patients received EGFR-TKI, we found that patients harboring lower CTC levels (<20.5) were associated with longer PFS (432 days, 95%CI:332.7-541.3) than those with higher CTC levels (≥20.5) (PFS: 308days, 95% CI: 245.3-370.7; P=0.017). Patients with CTC <20.5 had a DCR of 77.11% compared with 58.49% in CTC >20.5 groups (P=0.008), patients with CTC <20.5 had a ORR of 51.20% compared with 33.96% in CTC >20.5 groups (P=0.029). Decreased CTC values correlated well with partial response after one month or three months’ treatment of EGFR-TKI (P=0.0082 and P=0.0023), but not with stable disease (P=0.1843 and P=0.8606). Multivariate analysis showed that CTC level was an independent prognostic factor for PFS (CTC level<20.5 vs ≥20.5, hazard ratio, 0.497; P=0.014). The change of CTCs correlated significantly with radiological response. This strategy may enable non-invasive, predictive and prognostic, specific biomarker in patients undergoing targeted therapies.

Exosomal TMEM88 Protein As a Potential Biomarker in Liquid Biopsy for Non-Small-cell Lung Cancer

Tumor-derived exosomal proteins as diagnostic biomarkers in non-small cell lung cancer.

Glypican-1 in Serum-Derived Exosomes As a Potential Biomarker in Liquid Biopsy of Non-Small Cell Lung Cancer

Tumor-derived exosomal miR-155-5p and miR-658 in serum as diagnostic biomarkers for early-stage non-small cell lung cancer

PLA2G10 Incorporated in Exosomes Could Be Diagnostic and Prognostic Biomarker for Non-Small Cell Lung Cancer

Tumor-Derived Exosomal Mir-620 As a Diagnostic Biomarker in Non-Small-Cell Lung Cancer

Folate Receptor-Positive Circulating Tumor Cell Detected by LT-PCR Based Method As a Diagnostic Biomarker for Non-Small Cell Lung Cancer.

P2.03b-092 Predictive and Prognostic Effect of Circulating Tumor Cells in Non-Small Cell Lung Cancer Treated with Targeted Therapy: Topic: Biomarkers

Identification of Exosome Protein Panels As Predictive Biomarkers for Non-Small Cell Lung Cancer

Blood Tumor Mutation Burden Can Predict the Clinical Response to Immune Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer Patients

Folate Receptor-Positive Circulating Tumor Cells As a Predictive Biomarker for the Efficacy of First-Line Pemetrexed-Based Chemotherapy in Patients with Non-Squamous Non-Small Cell Lung Cancer

Tumor-associated exosomal miRNA biomarkers to differentiate metastatic vs. nonmetastatic non-small cell lung cancer

Overexpression and biological function of TMEM48 in non-small cell lung carcinoma

Proteomic Analysis of Plasma Exosomes in Patients with Non-Small Cell Lung Cancer

Cerebrospinal Fluid Exosomal Micrornas As Biomarkers for Diagnosing or Monitoring the Progression of Non-Small Cell Lung Cancer with Leptomeningeal Metastases

Exosomal Microrna-214 Expression and Its Prognostic Significance in Non-Small Cell Lung Cancer Patients

Tumor-Derived Exosomal Eif4e As a Biomarker for Survival Prediction in Patients with Non-Small Cell Lung Cancer.

Circulating exosomal microRNA-4497 as a potential biomarker for metastasis and prognosis in non-small-cell lung cancer

Circulating Exosomes Contain Protein Biomarkers of Metastatic Non-Small-cell Lung Cancer.

Plasma Exosomal Trna‐derived Fragments As Diagnostic Biomarkers in Non-Small Cell Lung Cancer

Exosomal LncRNA RP5-977B1 as a novel minimally invasive biomarker for diagnosis and prognosis in non-small cell lung cancer